Bottom line
XLV vs PHSYX: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and PHSYX (Putnam Global Health Care Fund) share a meaningful slice of their top holdings — about 67% by weight.
XLV is cheaper at 0.08% vs 0.79% — a difference of $71 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +8.1% for PHSYX (reporting dates differ).
Updated Nov 19, 2026
XLV vs PHSYX side by side
| XLV | PHSYX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | Franklin Templeton |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.79% |
| Annual cost per $10k | $8 | $79 |
| 10-yr cost on $10k (prospectus) | $103 | $978 |
| Max front load | None | 0% |
| 12b-1 fee | 0.02% | 0% |
| 1-yr return | +14.5% | +1.5% |
| 5-yr return (annualized) | +8.1% | +8.1% |
| 10-yr return (annualized) | +9.8% | +7.8% |
| Best quarter | +14.5% | — |
| Worst quarter | −12.7% | — |
| Net assets (fund) | $40.6B | $1.5B |
| Number of holdings | 65 | 115 |
| Portfolio turnover | 2% | 67% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
16 of XLV's top 25 holdings also appear in PHSYX's top 25.
| Holding | XLV | PHSYX |
|---|---|---|
| Eli Lilly & Co | 16.51% | 13.15% |
| Johnson & Johnson | 10.64% | 8.46% |
| AbbVie Inc | 7.74% | 6.05% |
| UnitedHealth Group Inc | 6.57% | 6.93% |
| Merck & Co Inc | 5.52% | 4.88% |
| Amgen Inc | 3.40% | 1.11% |
| Thermo Fisher Scientific Inc | 3.24% | 4.50% |
| Gilead Sciences Inc | 2.73% | 2.63% |
| Intuitive Surgical Inc | 2.45% | 4.04% |
| CVS Health Corp | 2.30% | 2.74% |
| Vertex Pharmaceuticals Inc | 2.19% | 1.97% |
| Bristol-Myers Squibb Co | 2.05% | 1.75% |
| McKesson Corp | 1.58% | 2.14% |
| Boston Scientific Corp | 1.10% | 1.80% |
| HCA Healthcare Inc | 1.05% | 1.18% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
PHSYX top 10
- Eli Lilly & Co. — 13.15%
- Johnson & Johnson — 8.46%
- UnitedHealth Group, Inc. — 6.93%
- AbbVie, Inc. — 6.05%
- Novartis AG — 5.13%
- Merck & Co., Inc. — 4.88%
- AstraZeneca plc — 4.67%
- Thermo Fisher Scientific, Inc. — 4.50%
- Intuitive Surgical, Inc. — 4.04%
- Sanofi SA — 3.23%
FAQ
What is the difference between XLV and PHSYX?
Which is cheaper, XLV or PHSYX?
Should I own both XLV and PHSYX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.